Health Canada released a revised Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs on June 28, 2019, effective immediately. Revisions include clarifying additions on the requirements for cross-licensed products for an Administrative Certification Form and Letter of Authorization, a Drug Notification form and labelling.
Health Canada has also released an updated Good Label and Package Practices Guide for Prescription Drugs. The June 21, 2019 update introduces only administrative edits to the 2016 guidance on labelling and packaging of prescription pharmaceuticals, biologics, and radiopharmaceuticals under Health Canada’s Plain Language Labelling Initiative.
Related Publications & Articles
-
Proposal for modernizing clinical trial framework aims to improve access to new and innovative therapies in Canada
On December 20, 2025, Health Canada launched a consultation on modernizing the framework for clinical trials involving drugs for human use, including pharmaceuticals, biologics, radiopharmaceuticals, ...Read More -
Health Canada consultation on two draft guidance documents on terms and conditions for human and veterinary drugs and drug submissions based on promising evidence of clinical efficacy
As previously reported, in December 2024, Health Canada published its agile licensing amendments to the Food and Drug Regulations.Read More -
2025 highlights in Canadian life sciences IP and regulatory law
In 2025, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More
